Form 4: Inotiv CEO Robert Leasure Jr. Receives Stock Options and Restricted Stock Units

Inotiv's CEO, Robert Leasure Jr., was granted stock options and restricted stock units, as reported in a recent SEC Form 4 filing.

Summary

• Robert Leasure Jr., the President and CEO of Inotiv, Inc., received a grant of 300,000 restricted stock units on August 10, 2024, which will vest in full on February 1, 2026, contingent upon continued employment.
• On the same date, Leasure was also granted an employee stock option to purchase 300,000 shares of common stock at an exercise price of $1.61 per share.
• This stock option vests over three years: 40% on February 1, 2025, 30% on February 1, 2026, and 30% on February 1, 2027, subject to continued employment.
• Following these transactions, Leasure directly owns 1,052,909 shares of Inotiv common stock and indirectly owns 105,000 shares through an entity where he is the majority security holder.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and restricted stock units is a standard practice and suggests confidence in the company's future performance. However, it also represents potential dilution for existing shareholders.

Positives

• The grant of restricted stock units and stock options aligns the CEO's interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedules for both the restricted stock units and stock options encourage long-term commitment from the CEO.

Industry Context

Stock option and RSU grants are a common practice in the biotech and pharmaceutical services industry to incentivize and retain key executives. The vesting schedules are typical for such grants.

Comparison to Industry Standards

• Executive compensation packages, including stock options and restricted stock units, are standard practice in the pharmaceutical and biotechnology industries.
• Companies like Charles River Laboratories and WuXi AppTec also utilize similar equity-based compensation to align executive interests with shareholder value.
• The vesting schedules and grant sizes are generally comparable to industry norms for companies of Inotiv's size and stage of development.

Stakeholder Impact

• Shareholders may experience potential dilution due to the issuance of new shares upon the exercise of stock options and vesting of restricted stock units.
• Employees may view the executive compensation package as a sign of the company's commitment to its leadership.

Key Dates